All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Bright Peak Therapeutics Inc. closed a $107 million series B round to progress a pipeline of engineered cytokines, which are produced using a chemical synthesis method instead of classical recombinant protein production approaches.
Flagship Pioneering Inc., the serial biotech-founding investor that created RNA trailblazer Moderna Inc., is putting its money behind Senda Biosciences Inc. and a technology that aims create medicines by changing the way the body interacts with organisms such as plants and microbes. Senda has just announced the closing of a $98 million series B funding round, after completing a $55 million extension that brings total funding raised so far to $143 million.
Medtrace Pharma A/S raised $30 million in a series B round to ramp its platform for production, infusion and analysis of 15O-water in medical imaging. Swiss-based Swisscanto Invest, along with fund managers ATP and Bankinvest group from Denmark, are the lead investors. “We can now ramp our European and U.S. expansions plans in myocardial perfusion imaging and in other indications in need of perfusion data,” Martin Stenfeldt, CEO and co-founder of Medtrace, told BioWorld.
